Skip to content

NewAmsterdam Pharma Co N.V.

Public company
Headquarters
NARRDEN
Ticker
NAMS
CIK
0001936258

WARN notices since 2024

0
None on record

Workers affected since 2024

0
Across 0 notices

Executive changes, last 12 months

3
1 appointment, 2 departures

Last event

Aug 14, 2026
Executive departureCOO departs: Douglas Kling

Workers affected over time

Cumulative workers in WARN notices since 2024

Not enough notices to chart yet.

Leadership

Role and personSinceChange
COODouglas KlingAug 14, 2026Departed
principal accounting officerRobert W. GunningAug 14, 2026Appointed

Same industry and state, with recent events.

  1. Executive departure

    COO departs: Douglas Kling

    Douglas Kling, Chief Operating Officer of NewAmsterdam Pharma Co N.V., resigns the role, effective August 14, 2026. The company reported the change in an 8-K/A that cites Item 5.02.

    Role: Chief Operating Officer

    Source: SEC 8-K, filed Aug 14, 2026
  2. Executive appointment

    principal accounting officer appointed: Robert W. Gunning

    Robert W. Gunning was named principal accounting officer of NewAmsterdam Pharma Co N.V., effective August 10, 2026. Robert W. Gunning succeeds Louise Kooij. The company reported the change in an 8-K that cites Item 5.02.

    Role: principal accounting officer

    Source: SEC 8-K, filed Aug 14, 2026
  3. Executive departure

    principal accounting officer departs: Louise Kooij

    Louise Kooij, principal accounting officer of NewAmsterdam Pharma Co N.V., departs the role, effective August 31, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: principal accounting officer

    Source: SEC 8-K, filed Aug 14, 2026

Last verified Nov 8, 2026